VC Group diversifies portfolio to include probiotics and bird's nest products

VC Group, a leading company in the healthcare industry, has recently expanded its product portfolio to include probiotics and bird's nest products. This diversification will allow the company to enter new markets and strengthen its position in the industry.

Probiotics

Probiotics are live microorganisms that provide health benefits when consumed in adequate amounts. They have become increasingly popular in recent years, with many people taking them to improve digestive health and boost the immune system. VC Group's new line of probiotics will include a variety of strains to target specific health issues. The products will be marketed towards health-conscious individuals looking to improve their overall wellness.

The company has invested heavily in research and development to ensure the effectiveness and safety of their probiotics. The products will be manufactured in state-of-the-art facilities under strict quality control standards. VC Group is confident that their probiotics will be well-received by consumers and contribute significantly to their bottom line.

Bird's Nest Products

Bird's nest products are derived from the nests of certain species of swiftlets. These nests are known for their high nutritional value and are believed to provide a range of health benefits. VC Group's bird's nest products will be sourced from reputable suppliers and carefully processed to ensure maximum nutritional value.

The company plans to market their bird's nest products as a luxury item, targeting affluent consumers who are willing to pay a premium for high-quality, natural products. The products will be available in various forms, including bird's nest soup and capsules.

Market Potential

The probiotics and bird's nest markets have shown significant growth potential in recent years. The global probiotics market was valued at $49.4 billion in 2020 and is expected to grow at a CAGR of 6.8% from 2021 to 2028. The bird's nest market, on the other hand, is expected to reach $2.16 billion by 2025, growing at a CAGR of 5.1% from 2020 to 2025.

VC Group's entry into these markets is a strategic move to capitalize on this growth potential. The company's strong brand reputation and extensive distribution network will give them a competitive advantage over other players in the market.

Conclusion

The diversification of VC Group's product portfolio to include probiotics and bird's nest products is a smart move that will allow the company to tap into new markets and strengthen their position in the healthcare industry. With their investment in research and development and commitment to quality, VC Group is well-positioned to succeed in these new ventures.

专家表示，挑选益生菌产品时，要注意这几个参考标准：活菌量、活性高低，菌株种类的多少。充足的活菌数量才能够更好的调节肠胃菌群的平衡，据了解。目前卓岳宜君素益生菌是颇受欢迎的一款益生菌产品，卓岳宜君素益生菌每盒活菌含量高达20000亿，是目前活菌量高的益生菌产品，并且它的包装通过特殊工艺处理，采用了先进的冻干保活技术，有效提升益生菌的活性和稳定性， 而且这款益生菌含有16种益生菌和9种益生元，菌株种类多样，协同作用，更好的调理肠道，改善肠道健康。